Short answer
CARLSMED, INC. (CARL) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $22M (up 64.9% year over year) with net income of −$12M.
Q3 2026 key financials · XBRL
- Revenue
- $22M
- +64.9% YoY · +13.8% QoQ
- Net income
- −$12M
- −43.6% YoY · −16.5% QoQ
- Operating margin
- -58.9%
- Gross margin
- 77.3%
- EPS (diluted)
- −$0.45
- −157.0% YoY · −15.4% QoQ
Source: XBRL data from the CARLSMED, INC. (CARL) Q3 2026 10-Q on SEC EDGAR. USD.
CARLSMED, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $21.6M, up 64.9% YoY from $13.1M, driven by higher lumbar and cervical procedure volume
- Gross margin 77.3% vs 75.9% YoY, aided by lower contract-manufacturer fees and digital production efficiencies
- Worst profitability metric: operating margin negative 58.9% vs negative 69.1% YoY, with net loss $12.2M vs $8.5M
- Cash, restricted cash, investments and securities $80.3M, with $15.6M debt outstanding at quarter-end
- Nine-month operating cash outflow $29.0M, investing outflow $21.7M, primarily marketable-security purchases of $23.6M
Risk Factors
- No material changes to previously disclosed Annual Report risk factors
- Business operations vulnerable to unidentified risks and uncertainties
- Financial condition and cash flows could be negatively affected by realized risks
- Investment value exposed to adverse business, operational, and financial outcomes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CARLSMED, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.